Abstract

In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI). The potentially protective effect of increased BMI in CHF has been termed the obesity paradox or reverse epidemiology. This meta-analysis was conducted to examine the relationship between increased BMI and mortality in patients with CHF. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Two reviewers independently assessed studies for inclusion and performed data extraction. Nine observational studies met final inclusion criteria (total n = 28,209). Mean length of follow-up was 2.7 years. Compared to individuals without elevated BMI levels, both overweight (BMI approximately 25.0-29.9 kg/m(2), RR 0.84, 95% CI 0.79-0.90) and obesity (BMI approximately > or =30 kg/m(2), RR 0.67, 95% CI 0.62-0.73) were associated with lower all-cause mortality. Overweight (RR 0.81, 95% CI 0.72-0.92) and obesity (RR 0.60, 95% CI 0.53-0.69) were also associated with lower cardiovascular mortality. In a risk-adjusted sensitivity analysis, both obesity (adjusted HR 0.88, 95% CI 0.83-0.93) and overweight (adjusted HR 0.93, 95% CI 0.89-0.97) remained protective against mortality. Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. There is a need for prospective studies to elucidate mechanisms for this relationship.

Highlights

  • In patients with chronic heart failure (CHF), previous studies have reported reduced mortality rates in patients with increased body mass index (BMI)

  • Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study

  • Observational data suggest a protective effect of the updated 2008 Canadian Cardiovascular Society (CCS) Census Conference guidelines for the treatment and management of HF refer to the obesity paradox, they continue to recommend weight loss for obese patients with HF,[6] even though this recommendation is not supported by evidence from clinical trials

Read more

Summary

Methods

We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Scopus, and Web of Science to identify studies with contemporaneous control groups (cohort, case-control, or randomized controlled trials) that examined the effect of obesity on all-cause and cardiovascular mortality. Detailed search strategies were designed with the help of a research librarian to identify randomized control trials (RCTs) and observational studies examining the effect of overweight and obesity on total mortality in CHF. Register of Controlled Trials (1990-June 2007), MEDLINE (1966June 2007), EMBASE (1988-June 2007), Scopus (1966-June 2007) and Web of Science (1900-June 2007) were searched, reference lists of primary studies and review articles were scanned, and 3 experts in the field were contacted. Studies were included if they reported mortality in HF patients according to BMI category. We defined “underweight” as BMI of approximately b18.5 kg/m2; studies including patients with normal BMI levels of b23.0 kg/m2 were defined as “underweight/low-normal.” Studies comparing obese vs nonobese (ie, normal plus overweight vs obese) were excluded unless outcomes in the normal BMI population alone could be ascertained

Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.